171 related articles for article (PubMed ID: 23780657)
1. Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.
Salah S; Yaser S; Salem A; Al Mousa A; Abu Sheikha A; Sultan I
Med Oncol; 2013; 30(3):639. PubMed ID: 23780657
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience.
Ates O; Aksoy S; Yeter H; Sunar V; Kertmen N; Dizdar O; Turker A; Kars A
Indian J Cancer; 2017; 54(1):321-325. PubMed ID: 29199714
[TBL] [Abstract][Full Text] [Related]
3. Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma.
Kojima Y; Shimoi T; Seo T; Yazaki S; Okuya T; Ohtake Y; Okuma HS; Shimomura A; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Tamura K; Yoshida A; Iwata S; Kobayashi E; Kawai A; Fujiwara Y; Yonemori K
Oncology; 2022; 100(7):370-375. PubMed ID: 35405680
[TBL] [Abstract][Full Text] [Related]
4. Primary Metastatic Synovial Sarcoma: Experience of the CWS Study Group.
Scheer M; Dantonello T; Hallmen E; Vokuhl C; Leuschner I; Sparber-Sauer M; Kazanowska B; Niggli F; Ladenstein R; Bielack SS; Klingebiel T; Koscielniak E
Pediatr Blood Cancer; 2016 Jul; 63(7):1198-206. PubMed ID: 27003095
[TBL] [Abstract][Full Text] [Related]
5. Paediatric non-rhabdomyosarcoma soft tissue sarcomas: the prospective NRSTS 2005 study by the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Ferrari A; van Noesel MM; Brennan B; Zanetti I; Corradini N; Casanova M; Berlanga P; Merks JHM; Alaggio R; Schifflers S; Ramirez-Villar GL; Giraudo C; Burrieza GG; Safwat A; Bisogno G; De Salvo GL; Orbach D
Lancet Child Adolesc Health; 2021 Aug; 5(8):546-558. PubMed ID: 34214481
[TBL] [Abstract][Full Text] [Related]
6. Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
Moreau-Bachelard C; Campion L; Toulmonde M; Le Cesne A; Brahmi M; Italiano A; Mir O; Piperno-Neumann S; Laurence V; Firmin N; Penel N; Duffaud F; Chevreau C; Bertucci F; Narciso B; Dubray-Longeras P; Delcambre C; Saada-Bouzid E; Boudou-Rouquette P; Soulie P; Perrin C; Blay JY; Bompas E
ESMO Open; 2022 Apr; 7(2):100402. PubMed ID: 35202953
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.
Spurrell EL; Fisher C; Thomas JM; Judson IR
Ann Oncol; 2005 Mar; 16(3):437-44. PubMed ID: 15653701
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
9. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.
Rosen G; Forscher C; Lowenbraun S; Eilber F; Eckardt J; Holmes C; Fu YS
Cancer; 1994 May; 73(10):2506-11. PubMed ID: 8174046
[TBL] [Abstract][Full Text] [Related]
10. Systemic Treatment for Adults with Synovial Sarcoma.
Desar IME; Fleuren EDG; van der Graaf WTA
Curr Treat Options Oncol; 2018 Mar; 19(2):13. PubMed ID: 29516254
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Young RJ; Litière S; Lia M; Hogendoorn PCW; Fisher C; Mechtersheimer G; Daugaard S; Sciot R; Collin F; Messiou C; Grünwald V; Gronchi A; van der Graaf W; Wardelmann E; Judson I
Acta Oncol; 2017 Jul; 56(7):1013-1020. PubMed ID: 28431480
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
13. Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity.
Vlenterie M; Litière S; Rizzo E; Marréaud S; Judson I; Gelderblom H; Le Cesne A; Wardelmann E; Messiou C; Gronchi A; van der Graaf WT
Eur J Cancer; 2016 May; 58():62-72. PubMed ID: 26968015
[TBL] [Abstract][Full Text] [Related]
14. [Chemotherapy for pulmonary metastases of soft tissue sarcoma].
Kito M; Umeda T
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1701-6. PubMed ID: 9757195
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
[TBL] [Abstract][Full Text] [Related]
16. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
17. Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment.
Spillane AJ; A'Hern R; Judson IR; Fisher C; Thomas JM
J Clin Oncol; 2000 Nov; 18(22):3794-803. PubMed ID: 11078492
[TBL] [Abstract][Full Text] [Related]
18. Influence of neoadjuvant chemotherapy on prognosis of patients with synovial sarcoma.
Wu Y; Bi W; Han G; Jia J; Xu M
World J Surg Oncol; 2017 May; 15(1):101. PubMed ID: 28494784
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors that govern localized synovial sarcoma: a single institution retrospective study on 51 patients.
Yaser S; Salah S; Al-Shatti M; Abu-Sheikha A; Shehadeh A; Sultan I; Salem A; Sughayer M; Al-Loh S; Al-Mousa A
Med Oncol; 2014 Jun; 31(6):958. PubMed ID: 24770952
[TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Miser JS; Krailo MD; Tarbell NJ; Link MP; Fryer CJ; Pritchard DJ; Gebhardt MC; Dickman PS; Perlman EJ; Meyers PA; Donaldson SS; Moore S; Rausen AR; Vietti TJ; Grier HE
J Clin Oncol; 2004 Jul; 22(14):2873-6. PubMed ID: 15254055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
